-
Je něco špatně v tomto záznamu ?
The association between duration of and indications for proton pump inhibitor use and risk of gastric polyps
R. Kroupa, T. Pavlik, S. Konecny, B. Packova, M. Dastych, Z. Pavlovsky, J. Dolina
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- gastroskopie MeSH
- Helicobacter pylori * MeSH
- infekce vyvolané Helicobacter pylori * komplikace farmakoterapie MeSH
- inhibitory protonové pumpy škodlivé účinky MeSH
- lidé MeSH
- nádory žaludku * chemicky indukované epidemiologie komplikace MeSH
- polypy * chemicky indukované epidemiologie komplikace MeSH
- prospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: The development of fundic gland polyps (FGPs) is the most common side effect of long-term proton pump inhibitor (PPI) use; however, the effect of drug use characteristics and their impact on the risk of other gastric polyp development remain unclear. We aimed to identify the influence of PPI administration, as well as its duration and dose, in the development of gastric polyps. METHODS: A prospective cohort study was conducted on consecutive patients who underwent gastroscopy between September 2017 and August 2019. Detailed characteristics of gastric polyps, Helicobacter pylori infection, and PPI use were analyzed. RESULTS: Among the 2723 patients included, gastric polyps (75% FGPs, 22% hyperplastic) were detected in 16.4%, and 60% were prescribed PPI. The risk of FGPs and hyperplastic polyps according to the duration of PPI use were as follows: 2-5 years [odds ratio (95% confidence interval); 2.86 (2.00-4.11) and 2.82 (1.69-4.78)]; 6-9 years [7.42 (5.03-11.01) and 2.32 (1.05-4.78)]; ≥10 years [14.94 (10.36-21.80) and 3.52 (1.67-7.03)]. Multivariate analysis confirmed that the risk of FGPs was 17.16 (11.35-26.23) for ≥10 years of PPI use. Portal hypertension-related conditions were associated with hyperplastic polyps [4.99 (2.71-9.20)]. CONCLUSION: Duration of and indications for PPI use are the most predictive factors for the development of gastric polyps. Prolonged PPI use increases the risk of polyp development and the number of patients with polyps, which may burden endoscopic practice. Highly selected patients may require particular care despite minimal risk of dysplasia and bleeding generally.
Department of Internal Medicine and Gastroenterology University Hospital Brno
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno
Institute of Health Information and Statistics of the Czech Republic Prague
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016674
- 003
- CZ-PrNML
- 005
- 20231026105632.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MEG.0000000000002587 $2 doi
- 035 __
- $a (PubMed)37395234
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kroupa, Radek $u Department of Internal Medicine and Gastroenterology, University Hospital Brno
- 245 14
- $a The association between duration of and indications for proton pump inhibitor use and risk of gastric polyps / $c R. Kroupa, T. Pavlik, S. Konecny, B. Packova, M. Dastych, Z. Pavlovsky, J. Dolina
- 520 9_
- $a OBJECTIVES: The development of fundic gland polyps (FGPs) is the most common side effect of long-term proton pump inhibitor (PPI) use; however, the effect of drug use characteristics and their impact on the risk of other gastric polyp development remain unclear. We aimed to identify the influence of PPI administration, as well as its duration and dose, in the development of gastric polyps. METHODS: A prospective cohort study was conducted on consecutive patients who underwent gastroscopy between September 2017 and August 2019. Detailed characteristics of gastric polyps, Helicobacter pylori infection, and PPI use were analyzed. RESULTS: Among the 2723 patients included, gastric polyps (75% FGPs, 22% hyperplastic) were detected in 16.4%, and 60% were prescribed PPI. The risk of FGPs and hyperplastic polyps according to the duration of PPI use were as follows: 2-5 years [odds ratio (95% confidence interval); 2.86 (2.00-4.11) and 2.82 (1.69-4.78)]; 6-9 years [7.42 (5.03-11.01) and 2.32 (1.05-4.78)]; ≥10 years [14.94 (10.36-21.80) and 3.52 (1.67-7.03)]. Multivariate analysis confirmed that the risk of FGPs was 17.16 (11.35-26.23) for ≥10 years of PPI use. Portal hypertension-related conditions were associated with hyperplastic polyps [4.99 (2.71-9.20)]. CONCLUSION: Duration of and indications for PPI use are the most predictive factors for the development of gastric polyps. Prolonged PPI use increases the risk of polyp development and the number of patients with polyps, which may burden endoscopic practice. Highly selected patients may require particular care despite minimal risk of dysplasia and bleeding generally.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory protonové pumpy $x škodlivé účinky $7 D054328
- 650 12
- $a infekce vyvolané Helicobacter pylori $x komplikace $x farmakoterapie $7 D016481
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a Helicobacter pylori $7 D016480
- 650 12
- $a nádory žaludku $x chemicky indukované $x epidemiologie $x komplikace $7 D013274
- 650 12
- $a polypy $x chemicky indukované $x epidemiologie $x komplikace $7 D011127
- 650 _2
- $a gastroskopie $7 D005773
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pavlik, Tomas $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno $u Institute of Health Information and Statistics of the Czech Republic, Prague
- 700 1_
- $a Konecny, Stefan $u Department of Internal Medicine and Gastroenterology, University Hospital Brno
- 700 1_
- $a Packova, Barbora $u Department of Internal Medicine and Gastroenterology, University Hospital Brno
- 700 1_
- $a Dastych, Milan $u Department of Internal Medicine and Gastroenterology, University Hospital Brno
- 700 1_
- $a Pavlovsky, Zdenek $u Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Dolina, Jiri $u Department of Internal Medicine and Gastroenterology, University Hospital Brno
- 773 0_
- $w MED00001618 $t European journal of gastroenterology & hepatology $x 1473-5687 $g Roč. 35, č. 8 (2023), s. 829-835
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37395234 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105626 $b ABA008
- 999 __
- $a ok $b bmc $g 2000285 $s 1203036
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 35 $c 8 $d 829-835 $e 20230606 $i 1473-5687 $m European journal of gastroenterology & hepatology $n Eur J Gastroenterol Hepatol $x MED00001618
- LZP __
- $a Pubmed-20231013
